Ironwood Pharmaceuticals
IRWD
137 hedge funds and large institutions have $1.73B invested in Ironwood Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 54 increasing their positions, 35 reducing their positions, and 26 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 35
28% more call options, than puts
Call options by funds: $4.3M | Put options by funds: $3.35M
4% less funds holding
Funds holding: 142 → 137 (-5)
19% less capital invested
Capital invested by funds: $2.14B → $1.73B (-$403M)
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$35.5M |
| 2 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$25.7M |
| 3 |
BM
Bridger Management
New York
|
+$23.2M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$18.5M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$19.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$14.4M |
| 3 |
Morgan Stanley
New York
|
-$12M |
| 4 |
JP Morgan Chase
New York
|
-$9.31M |
| 5 |
FAM
Fred Alger Management
New York
|
-$7.84M |
IRWD Hedge Fund Activity: Q2 2015 in Review
137 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2015, worth a combined $1.73B — down 19% from $2.14B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of IRWD and 21 opened new positions — a net loss of 5 holders — while 35 trimmed existing stakes and 54 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $35.5M. The largest seller was Millennium Management, cutting an estimated $19.3M.
- 137 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2015, down from 142 in Q1 2015.
- Funds reported $1.73B of Ironwood Pharmaceuticals stock for Q2 2015, down 19% quarter-over-quarter.
- 21 funds opened new Ironwood Pharmaceuticals positions in Q2 2015 and 26 closed out, a net change of -5 holders.
- The largest Ironwood Pharmaceuticals buyer in Q2 2015 was T. Rowe Price Associates, an estimated $35.5M added.
- The largest Ironwood Pharmaceuticals seller in Q2 2015 was Millennium Management, an estimated $19.3M sold.
Based on aggregated 13F filings for Q2 2015.